Carelon Research
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Carelon Research sits in the top decile of US sponsors by registered trial count (#377 of 15,742 sponsors by registered trial count).
Carelon Research: 50 sponsored US clinical trials, 1 recruiting.
Carelon Research sponsors 50 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 36 completed. 15 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Congenital Heart Disease, with 2 trials.
Top-decile sponsor footprint
Carelon Research ranks in the top decile of sponsors by registered trial count (#377 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
36 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
50 total, page 1 of 1
A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study
NCT07525843
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT04702373
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
NCT05287412
Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)
NCT07582861
BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease
NCT07582848
Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)
NCT05312177
Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women
NCT04475718
Use of Oxandrolone to Promote Growth in Infants With HLHS
NCT04090697
Dyslipidemia of Obesity Intervention in Teens
NCT02956590
Type 1 Teamwork: A Tool for Parents of Adolescents With Type 1 Diabetes
NCT04073914
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters
NCT02381509
Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
NCT02060630
A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics
NCT01915277
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
NCT01912534
Schizophrenia Cognition Scale Development
NCT02118571
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
NCT01910389
Training in Exercise Activities and Motion for Growth
NCT01917084
Mechanism and Repository Study for the Red Cell Storage Duration Study
NCT01541319
Composites and Urinary Bisphenol-A Study
NCT01484132
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
NCT01178333
Red Cell Storage Duration Study
NCT00991341
THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)
NCT00999245
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
NCT00991939
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
NCT00872833
Preventing Acute Chest Syndrome by Transfusion Feasibility Study
NCT00951808
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
NCT00799773
Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
NCT00872170
Assessment of Pain in People With Thalassemia
NCT00872339
Value of Urodynamic Evaluation
NCT00803959
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
NCT00756821
Mixed Incontinence: Medical Or Surgical Approach?
NCT00803270
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
NCT00627393
Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia
NCT00661726
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
NCT00594685
Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study
NCT00661804
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
NCT00429364
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
NCT00094302
Rituximab to Treat Severe Hemophilia A
NCT00331006
TOMUS-Trial Of Mid-Urethral Slings
NCT00325039
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
NCT00115349
Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network
NCT00123071
Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network
NCT00115934
Behavior Enhances Drug Reduction of Incontinence (BE-DRI)
NCT00090584
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00128713
Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)
NCT00502788
Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
NCT00064662
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
NCT00000623
ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly
NCT00298558
The Children's Amalgam Trial
NCT00065988
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 12 |
| Phase 4 | 3 |
What is open in the Carelon Research pipeline
1 recruiting of 50 indexed (2% open); 36 completed (72%).
Phase mix: 15 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Congenital Heart Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Carelon Research: open-pipeline peers nationwide
Peers matched on 50 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Carelon Research sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 50 trials (± recruiting share)
- Repros Therapeutics · 50 trials · 0% recruiting
- The University of Texas at Dallas · 50 trials · 28% recruiting
- Colgate Palmolive · 51 trials · 6% recruiting
- MedtronicNeuro · 51 trials · 4% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Sanofi Pasteur, a Sanofi Company · 2% recruiting · 153 trials
- Cynosure · 2% recruiting · 49 trials
- Genzyme, a Sanofi Company · 2% recruiting · 196 trials
- PTC Therapeutics · 2% recruiting · 52 trials
Related
What to do with this Carelon Research page
50 registered trials is a research-attention snapshot, not an endorsement of Carelon Research or any single study.
- 1 of Carelon Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Congenital Heart Disease is the condition Carelon Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Congenital Heart Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Carelon Research pipeline card: 50 registered trials from official public datasets.Report a data error.